(±)5-iPF2α-VI-d11
目录号 : GC46263An internal standard for the quantification of (±)5-iPF2α-VI
Cas No.:936565-17-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(±)5-
1.Morrow, J.D., Hill, K.E., Burk, R.F., et al.A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanismProc. Natl. Acad. Sci. U.S.A.87(23)9383-9387(1990) 2.Parchmann, S., and Mueller, M.J.Evidence for the formation of dinor isoprostanes E1 from α-linolenic acid in plantsThe Journal of Biological Chemisty27332650-32655(1998) 3.Delanty, N., Reilly, M., Pratico, D., et al.8-Epi PGF2α: Specific analysis of an isoeicosanoid as an index of oxidant stress in vivoBritish Journal of Clinical Pharmacology4215-19(1996) 4.Reilly, M.P., Barry, P., Lawson, J.A., et al.Urinary 8-epi PGF2α: An index of oxidant stress in vivoFibrinolysis & Proteolysis1181-84(1997) 5.Reilly, M.P., Pratico, D., Delanty, N., et al.Increased formation of distinct F2 isoprostanes in hypercholesterolemiaCirculation982822-2828(1998) 6.Li, H., Lawson, J.A., Reilly, M., et al.Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urineProceedings of the National Academy of Sciences of the United States of America96(23)13381-13386(1999) 7.Lawson, J.A., Li, H., Rokach, J., et al.Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8,12-iso-isoprostane F2α-VI, in human urineThe Journal of Biological Chemisty27329295-29301(1998) 8.PraticÒ, D., Barry, O.P., Lawson, J.A., et al.IPF2α-I: An index of lipid peroxidation in humansProceedings of the National Academy of Sciences of the United States of America953449-3454(1998)
Cas No. | 936565-17-2 | SDF | |
Canonical SMILES | CCCCC/C=C\C[C@H]1C(O)CC(O)[C@H]1\C=C\C(O)CCCC(=O)O | ||
分子式 | C20H23D11O5 | 分子量 | 365.6 |
溶解度 | DMF: 50 mg/ml,DMSO: 50 mg/ml,Ethanol: 50 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7352 mL | 13.6761 mL | 27.3523 mL |
5 mM | 0.547 mL | 2.7352 mL | 5.4705 mL |
10 mM | 0.2735 mL | 1.3676 mL | 2.7352 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。